EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$9.30
+2.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
81.6x
EV/EBITDA
−71.7x
Market Cap
$614.27M
MomentumView details →
1D Return
+2.76%
YTD Return
+37.67%
RSI (14)
71.5
ValuationView details →
P/E (Fwd)
81.6x
EV/EBITDA
−71.7x
Market Cap
$614.27M
RSI (14)
71.5
MomentumView details →
1D Return
+2.76%
YTD Return
+37.67%
SummaryUpdated Jun 1, 2026
Evolus, Inc. (NASDAQ:EOLS) is a performance beauty company founded in 2012 and headquartered in Newport Beach, California. The company went public in February 2018 and has established itself as a significant player in the medical aesthetics industry. Evolus focuses on developing and commercializing innovative injectable products for physicians and their patients, primarily in the United States market. The company has evolved from a single-product neurotoxin manufacturer to a comprehensive aesthetics platform offering both neurotoxin and dermal filler solutions.
Similar companies
Latest newsMore news →
Evolus, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting strong performance and its third consecutive quarter of positive adjusted EBITDA.30d agoEvolus expanded its partnership with Symatese by amending their licensing and distribution agreement to gain exclusive rights to commercialize the Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand.31d ago